Results from the company’s Explore44 trial (NCT05670730) found that targeted delivery of del-zota, an antibody oligonucleotide conjugate (AOC), saw an approximate increase of 40% in exon 44 ...

The company announced positive topline data from its Phase 1/2 EXPLORE44 trial for del-zota, a potential treatment for Duchenne muscular dystrophy, showing statistically significant improvements ...

The company announced positive topline data from its Phase 1/2 EXPLORE44 trial for del-zota, a potential treatment for Duchenne muscular dystrophy, showing statistically significant improvements in ...

It is currently undergoing evaluation in a potentially registrational 25-patient Phase 1/2 trial (EXPLORE44) with solid interim results to date and now fully enrolled, demonstrating a 25% increase ...

Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy (DMD). Results from the company’s ...

The EXPLORE44 study enrolled DMD patients with DMD mutations amenable to exon 44 skipping (DMD44), a group that accounts for around 6% of all DMD cases in the US. It showed a statistically ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...

Avidity Biosciences, Inc. announced positive results from their phase 1/2 EXPLORE44 trial of del-zota in 23 patients living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44), ...